In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients
NCT05617209
·
clinicaltrials.gov ↗
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Hemophilia
Interventions
OTHER:
thrombin generation measurement
Sponsor
Centre Hospitalier Universitaire de Saint Etienne